Parabacteroides

A Gram-negative, obligate anaerobic genus within the Bacteroidetes phylum, closely related to bacteroides fragilis. The best-characterized species, P. distasonis, has emerged as a key anti-inflammatory commensal with significant roles in bile acid metabolism and metabolic health. Parabacteroides shows a distinctive pattern of being depleted in metabolic and autoimmune diseases while enriched in certain cancers, making it part of the "opposite directionality" signature described across disease categories.

Role in Gut Ecosystem

• Member of the core Bacteroidetes community that dominates the human colon, contributing to polysaccharide degradation and bile acid biotransformation.
• P. distasonis deconjugates primary bile acids and produces secondary bile acids including lithocholic acid, influencing fxr and TGR5 signaling pathways that regulate immune tone and metabolic homeostasis.
• Produces short chain fatty acids (primarily succinate and acetate) that feed cross-feeding networks supporting butyrate producers like faecalibacterium prausnitzii.
• Contributes to colonization resistance against pathogens through niche competition and bile acid-mediated inhibition.

Disease Associations

Metabolic Protection

• Depleted in obesity and type 2 diabetes, where its loss correlates with impaired bile acid signaling and metabolic inflammation.
• P. distasonis supplementation in mouse models improves glucose tolerance, reduces adiposity, and ameliorates hepatic steatosis via bile acid-FXR-FGF15 axis modulation.

Autoimmune Disease

• Significantly depleted in graves disease alongside bacteroides fragilis and alistipes, contributing to the pro-inflammatory gut environment that drives thyroid autoimmunity ^[1].
• Decreased in multiple sclerosis at baseline; B-cell depletion therapy (ocrelizumab) further reduces Parabacteroides as the overall microbiome shifts toward Firmicutes restoration ^[2].

Cancer -- Opposite Directionality

• Shows true opposite directionality in the Islam 2022 meta-analysis: increased in cancer cohorts but decreased in autoimmune disease cohorts ^[3].
• Enriched in colorectal cancer progression — identified among genera contributing to CRC stage advancement alongside Proteus and alistipes ^[4].
• This paradox may reflect context-dependent bile acid metabolism: protective secondary bile acids in healthy mucosa versus tumor-promoting deoxycholic acid in the dysbiotic cancer microenvironment.

Lipid Metabolism

• Mendelian randomization evidence supports causal relationships between Parabacteroides abundance and circulating lipid profiles, consistent with its role in bile acid-mediated lipid homeostasis ^[5].

Premenstrual and Mood Symptoms

• Parabacteroides abundance is associated with premenstrual symptom patterns in reproductive-age women, implicating it in the gut-brain-hormone axis of PMS/pmdd ^[6].

Fibromyalgia

• Altered Parabacteroides abundance identified in the fibromyalgia gut microbiome signature, consistent with its broader pattern of depletion in inflammatory and pain-associated conditions ^[7].

Key Metabolites

• Secondary bile acids (lithocholic acid, ursodeoxycholic acid) — immunomodulatory via FXR/TGR5
• Succinate — intermediate metabolite; fuel for cross-feeding networks
• Acetate — contributes to gut barrier maintenance and systemic anti-inflammatory signaling

Key Sources

• ^[8]

Connections

• bacteroides fragilis — sister taxon within Bacteroidales; co-depleted in autoimmune disease
• alistipes — co-depleted in Graves' disease; shared bile acid metabolic niche
• colorectal cancer — paradoxical enrichment in cancer despite anti-inflammatory properties
• graves disease — depleted, contributing to immune imbalance
• multiple sclerosis — reduced at baseline in MS patients
• type 2 diabetes — depletion linked to metabolic inflammation
• short chain fatty acids — acetate producer; supports cross-feeding with butyrate producers
• dysbiosis — its loss is a marker of both metabolic and autoimmune dysbiosis
• inflammation — anti-inflammatory via bile acid and SCFA signaling